Matthew F. Buas - Concepedia

Author

Matthew F. Buas

Also Known As

Bernstein, Jonine L, De Dieu Tapsoba, Jean, Gammon, Marilie D, Gammon, Marilie D., M. F. Buas, Matthew Buas, Matthew F Buas, Matthew F. Buas, Matthew F. Buas, Reid, Brian J.

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Fred Hutch Cancer Center University of Washington Roswell Park Comprehensive Cancer Center QIMR Berghofer Medical Research Institute Karolinska Institutet

About

Matthew F. Buas is an author at Fred Hutch Cancer Center specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	526
2	Public Health	5	5	220
3	Engineering	1	1	35
4	Biostatistics	1	1	14
5	Clinical Nutrition	1	1	55

Matthew F. Buas

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett’s oesophagus and provides insights into clinical heterogeneity in reflux diagnosis Jue‐Sheng Ong, Jiyuan An, Xikun Han, Gut	2021	179
Inhibition of myogenesis by Notch: Evidence for multiple pathways Matthew F. Buas, Shara Kabak, Tom Kadesch Journal of Cellular Physiology	2008	93
The Notch Effector Hey1 Associates with Myogenic Target Genes to Repress Myogenesis Matthew F. Buas, Shara Kabak, Tom Kadesch Journal of Biological Chemistry	2009	87
Determining Risk of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants Jing Dong, Matthew F. Buas, Puya Gharahkhani, Gastroenterology Genetic VariantsEpidemiologyEsophagusCancer EpidemiologyGastrointestinal Oncology	2017	86
Salivary metabolite profiling distinguishes patients with oral cavity squamous cell carcinoma from normal controls Pawadee Lohavanichbutr, Yuzheng Zhang, Pei Wang, PLoS ONE Salivary MetaboliteNormal ControlsSquamous Cell CarcinomaMedicineOral Cavity	2018	85
Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors Matthew F. Buas, Haiwei Gu, Danijel Djukovic, Gynecologic Oncology OncologyMedicineBiomarker TargetGynecologyPathology	2015	70
Targeted plasma metabolome response to variations in dietary glycemic load in a randomized, controlled, crossover feeding trial in healthy adults Sally Barton, Sandi L. Navarro, Matthew F. Buas, Food & Function NutritionNutritional EpidemiologyPlasma Metabolome ResponseMetabolomic ProfilingCaloric Restriction	2015	55
Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma Matthew F. Buas, Qianchuan He, Lisa Johnson, Gut	2016	49
FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women? Allyson C. Espinal, Matthew F. Buas, Dan Wang, Breast Cancer Research and Treatment Breast OncologyCancer EpidemiologyMedicinePathologyFoxa1 Hypermethylation	2017	42
Survival disparities among racial/ethnic groups of women with ovarian cancer: An update on data from the Surveillance, Epidemiology and End Results (SEER) registry Ashley E. Stenzel, Matthew F. Buas, Kirsten B. Moysich Cancer Epidemiology Cancer EpidemiologySurvival DisparitiesMedicineEpidemiology Of CancerReproductive Health	2019	39

Page 1